AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today the publication of data from a preclinical study demonstrating the combination of INGN 241, Introgen’s mda-7/IL-24 cancer product candidate, and Velcade® (Bortezemib) resulted in increased tumor cell killing in human ovarian cancer cells. The results from the study appeared in an advanced on-line article in Cancer Gene Therapy and provide a new molecularly targeted approach to specifically destroy cancer cells. The research was performed in the laboratory of Dr. Rajagopal Ramesh, associate professor in the Department of Thoracic and Cardiovascular Surgery at M.D. Anderson Cancer Center.
